2. Jacobson CA, Locke FL, Ghobadi A, et al. Long-Term (5 Year) Overall Survival in Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B-Cell Lymphoma (LBCL)....
Andrew J Davies, Louise Stanton, Josh Caddy, et al. Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of...
DLBCL is one of the most common subtypes of non-Hodgkin lymphoma (NHL) in adults and is highly heterogeneous malignancy in both clinical manifestations and prognosis. The current standard treatment, immunotherapy, offers patients with DLBCL a five-year progression-free survival rate of 60%-65% and...
DLBCL is one of the most common subtypes of non-Hodgkin lymphoma (NHL) in adults and is highly heterogeneous malignancy in both clinical manifestations and prognosis. The current standard treatment, immunotherapy, offers patients with DLBCL a five-year progression-free survival rate of 60%-65% and...
DLBCL is one of the most common subtypes of non-Hodgkin lymphoma (NHL) in adults and is highly heterogeneous malignancy in both clinical manifestations and prognosis. The current standard treatment, immunotherapy, offers patients with DLBCL a five-year progression-free survival rate of 60%-65% and...
Survival analysis was performed using the Kaplan- Meier method and log-rank test. The Cox model was used for analysis of prognostic factors. The toxicities were scored using the RTOG criteria. ResultsThe median follow-up was 64 months. The 5-year locoregional control (LRC), overall survival ...
HDCT试验的荟萃分析Grebetal.,2007,CancerTreatRev演讲概要DLBCL现在美罗华时代OverallSurvivalZucca,IOSIdatabase2009DLBCL:可治愈的疾病预后因素:IPI预后因素年龄>60行为状态≥2LDH>1x正常III或IV期>1个结外病灶Shippetal.NEnglJMed.1993IPI在利妥昔单抗时代是否仍旧有效 ?OSIPIR-IPI(R=revised)Sehnetal.:NO!=0-1...
(DLBCL), which has a median age of diagnosis of 66 years, with over half of patients older than 65 years.1Despite this, the outcomes of DLBCL in older adults are suboptimal, with a 5-year relative survival of 54.3% in patients who are older than 65 years compared with 78.4% in those...
弥漫大B细胞淋巴瘤(DLBCL)过去现在和将来上海瑞金医院沈志祥东方和西方淋巴瘤的发病率B-aggressiveB-indolentT-cellWestEastNakamura et al, 2000DLBCL过去:CHOP是10年前标准的治疗100%80%60%OVERALL SURVIVAL40%Regimen pts deaths 3-yr OS Pro-MACE-CytaBOM 225 88 54%MACOP-B 223 93 52%m-BACOD 233 97 ...
The 5-years relative survival rates decreases from 78 % in those younger than 65 years to 62 % in those older than 65 years. The occurrence of all Non-Hodkgin's Lymphomas (NHL) has been rising from 10 to over 20 newly diagnosed patients per 100,000 from 1975 to 2010. For patients ...